Naslov
Mometasone furoate/formoterl reduces asthma deteriorations and improves lung function

Autori
Meltzer, Eli ; Kuna, Piotr ; Nolte, Hendrik ; Dimitrov, Vasil ; Georgiev, Ognian ; Georgiev- Marinov R ; Kostov, RV ; Nikolova Georgieva P ; Ivanova, GK ; Ilieva_Fartumora, VD ; Markova, NZ ; Metev, H ; Chema, A ; Sussman, Gordon ; Yang, V ; Hebert, J ; Cardona-Arango, G ; Giraldo- Estrada, H ; Cheng, WCC ; Ahel, V ; Ćaleta, D ; Ćepin- Bogović, Jasna ; Pavičić, Fadila ; Stipić- Marković, Asja ; Tudorić, Neven ; Backer, V ; Cherrez, MI ;

Izvornik
European Respiratory Journal (0903-1936) 39 (2012); 279-289

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Asthma control, asthma deteriorationasthma exacerbation, efficacy, mometasone, furoate/formoterol combinationtherapy, randomised clinical trial

Sažetak
This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function. This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 yrs with not well-controlled asthma on low- dose inhaled corticosteroids. After a 2-3-week open-label run-in (MF 100 μg b.i.d.), 746 subjects were randomised to receive placebo, F 10 μg, MF 100 μg or MF/F 100/10 μg b.i.d. Co-primary end- points were time to first asthma deterioration (MF/F versus F to assess effect of MF) and change in forced expiratory volume in 1 s (FEV(1)) area under the curve of serial spirometry measurements over the 12-h period following the morning dose (AUC(0-12h)) (baseline to week 12 ; MF/F versus MF to assess effect of F). The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time to first asthma deterioration (p<0.001). Asthma deterioration incidence was also reduced with MF/F versus MF (p=0.006). The therapeutic effect of F in the combination was demonstrated by MF/F versus MF in FEV(1) AUC(0-12h) change (4.00 versus 2.53 L•h, respectively ; p=0.001). MF/F treatment also resulted in a marked improvement in health-related quality of life. MF/F 100/10 μg b.i.d. treatment showed greater clinical efficacy than its individual components or placebo ; both components contributed to the efficacy of MF/F.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA